Comparison of methodology of clinical studies of drug treatments
| Reference | Sample size | Inclusion criteria | Exclusion criteria | Mean initial K (mmol/l) | Crossover design |
|---|---|---|---|---|---|
| IHD = ischaemic heart disease, DM = diabetes mellitus, ACE = angiotensin converting enzyme. | |||||
| 2 | 10 | CRF | 5.81 | yes | |
| 3 | 8 | CRF | ACE inhibitors | 6.3 | yes |
| 4 | 13 | Child <17 y; ARF and CRF | 6.7 | no | |
| 5 | 44 | ARF and CRF | IHD, DM | 7.0 | no |
| 6 | 15 | CRF | 5.53 | yes | |
| 7 | 5 | CRF | DM, IHD | 4.29 | yes |
| 8 | 17 | CRF (82%), ARF (18%) | 7.02 | no | |
| 9 | 34 | CRF | 5.8 | no | |
| 10 | 12 | CRF | DM | 5.56 | yes |
| 11 | 44 | CRF (50%), ARF (50%) | DM, IHD | 7.0 | no |
| 12 | 10 | CRF | ACE inhibitors | 5.62 | yes |
| 13 | 10 | CRF; Able to cooperate | DM | 6.5 | no |
| 14 | 15 | Children CRF (27%), ARF (73%) | Arrhythmias | 6.6 | no |
| 15 | 11 | CRF | Hypertension, IHD, DM β agonist, steroids, xanthine derivatives | 5.9 | yes |
| 16 | 9 | CRF | DM, β blockers, digoxin, ACE inhibitors | 5.99 | yes |
| 17 | 45 | CRF | DM, asthma, IHD | >6.0 | no |
| 18 | 9 | CRF | DM | 6.33 | no |